59
Views
1
CrossRef citations to date
0
Altmetric
Review

Hypertrophic osteoarthropathy: classification, diagnostic features, and treatment options

, , &
Pages 831-836 | Received 15 Mar 2016, Accepted 03 Jun 2016, Published online: 07 Jul 2016

References

  • Marie P. De l’ostéo-arthropathie hypertrophiante pneumique. Rev Med. 1890;10:1–36.
  • Von Bamberger E. Veränderungen der Röhrenknochen bei Bronchiektasiein. Wien Klin Wochenschr. 1889;2:226.
  • Morgan B, Coakley F, Finlay DB, et al. Hypertrophic osteoarthropathy in staging skeletal scintigraphy for lung cancer. Clin Radiol. 1996;51:694–697.
  • Martínez-Lavín M, Bobadilla M, Casanova J, et al. Hypertrophic osteoarthropathy in cyanotic congenital heart disease: its prevalence and relationship to bypass of the lung. Arthritis Rheum. 1982;25:1186–1193.
  • Wijesekera VA, Radford DJ. Hypertrophic osteoarthropathy in eisenmenger syndrome. Congenit Heart Dis. 2013;8:F65–F69.
  • Mebus S, Schulze-Neick I, Oechslin E, et al. The adult patient with eisenmenger syndrome: a medical update after Dana Point Part II: medical treatment - study results. Curr Cardiol Rev. 2010 Nov;6(4):356–362.
  • Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin. 1993 Nov;11(4):689–699.
  • Altman RD, Tenenbaum J. Hypertrophic osteoarthropathy. In: Edward B, editor. Harris: Kelley’s textbook of rheumatology. Vol. 17. 7th ed. Philadelphia (PA): W.B. Saunders; 2005. p. 48–52.
  • Lo Monaco A, Govoni M, Trotta F. Digital clubbing or digital “pseudo-clubbing” in systemic sclerosis. J Clin Rheumatol. 2006;12:97.
  • Sridar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest. 1998;114:1535–1537.
  • Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet. 1987;2:1434–1435.
  • Atkinson S, Fox S. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203:721–728.
  • Martinez-Lavin M. Exploring the cause of the most ancient clinical sign of medicine: finger clubbing. Semin Arthritis Rheum. 2007;36:380–385.
  • Silveri F, De Angelis R, Argentati F, et al. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol. 1996;15:435–439.
  • Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40:789–793.
  • Zhang Z, Xia W, He J, et al. Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet. 2012;90:125–132.
  • Zhang Z, He JW, Fu WZ, et al. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2013;98:E923-933.
  • Seifert W, Kuhnisch J, Tuysuz B, et al. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat. 2012;33:660–664.
  • Diggle CP, Parry DA, Logan CV, et al. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat. 2012;33:1175–1181.
  • Busch J, Frank V, Bachmann N, et al. Mutations in the prostaglandin transporter SLCO2A1 cause primary hypertrophic osteoarthropathy with digital clubbing. J Invest Dermatol. 2012;132:2473–2476.
  • Sasaki T, Niizeki H, Shimizu A, et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci. 2012;68:36–44.
  • Nomura T, Lu R, Pucci ML, et al. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol. 2004;65:973–978.
  • Schuster VL. Prostaglandin transport. Prostaglandins Other Lipid Mediat. 2002;68–69:633–647.
  • Kanai N, Lu R, Satriano JA, et al. Identification and characterization of a prostaglandin transporter. Science. 1995;268:866–869.
  • Tai HH, Ensor CM, Tong M, et al. Prostaglandin catabolizing enzymes. Prostaglandins & Other Lipid Mediators. 2002;68–69:483–493.
  • Ferreira SH, Vane JR. Prostaglandins: their disappearance from and release into the circulation. Nature. 1967;216:868–873.
  • Pilbeam CC, Raisz LG. Prostaglandins, leukotrienes and bone. In: Curtis-Prior P, editor. The Eicosanoids. Cambridge: Cambridge Research Institute and Anglia Polytechnic University; 2004. p. 289–298.
  • Crevenna R, Quittan M, Hulsmann M, et al. Hypertrophic osteoarthropathy caused by PGE1 in a patient with congestive heart failure during cardiac rehabilitation. Wien Klin Wochenschr. 2002;114:115–118.
  • Currie AE, Gallagher PJ. The pathology of clubbing: vascular changes in the nail bed. Br J Dis Chest. 1988;82:382–385.
  • Stein RA. Digital clubbing: finally a gene. Nature Genetics. 2008;40:789–793.
  • Martínez-Lavín M, Matucci-Cerinic M, Jajic I, et al. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993;20:1386–1387.
  • Kerith E, Spicknall BA, Zirwas MJ, et al. Clubbing: an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance. J Am Acad Dermatol. 2005;52:1020–1028.
  • Martinez-Lavin M, Vargas A, Rivera-Vinas M. Hypertrophic osteoarthropathy: a palindrome with a pathogenic connotation. Current Opinion in Rheumatology. 2008;20:88–91.
  • Compton RF, Sandborn WJ, Yang H, et al. A new syndrome of Crohn’s disease and pachydermoperiostosis in a family. Gastroenterology. 1997;112:241:9.
  • Kitis G, Thompson H, Allan RN. Finger clubbing in inflammatory bowel disease: its prevalence and pathogenesis. Br Med J. 1979;2:825–828.
  • Bachmeyer C, Blum L, Cadranel JF, et al. Myelofibrosis in a patient with pachydermoperiostosis. Clin Exp Dermatol. 2005;30:646–648.
  • Martínez-Lavín M, Vargas AS, Cabré J, et al. Features of hypertrophic osteoarthropathy in patients with POEMS syndrome. A metaanalysis. J Rheumatol. 1997;24:2267–2268.
  • Steurer M, Zoller H, Augustin F, et al. Increased angiogenesis in chronic _ idiopathic myelofibrosis: vascular endothelial growth factor as a prominentangiogenic factor. Hum Pathol. 2007;38:1057–1064.
  • Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn’s disease. Inflamm Bowel Dis. 2004;10:573–577
  • Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow- Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390–1397.
  • Pineda C, Martínez-Lavín M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin North Am. 2013;39:383–400.
  • Pineda C. Diagnostic imaging in hypertrophic osteoarthropathy. Clin Exp Rheumatol. 1992;10(Suppl 7):27–33.
  • Ulusakarya A, Gumus Y, Brahmi N, et al. Symptoms in cancer patients and an unusual tumor: case 1. Regression of hypertrophic pulmonary osteoarthropathy following chemotherapy for lung metastases of a nasopharyngeal carcinoma. J Clin Oncol. 2005;23:9422–9423.
  • King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clin Lung Cancer. 2008;9:179–182.
  • Ammital H, Applbaum YH, Vasiliey L, et al. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol. 2004;23:330–332.
  • Suzuma T, Sakurai T, Yoshimura G, et al. Pamidronate induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs. 2001;12:731–734.
  • Guyot-Drouot MH, Solau-Gervais E, Cortet B, et al. Rheumato- logic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates. J Rheumatol. 2000;27:2418–2423.
  • Johnson SA, Spiller PA, Faull CM. Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide. Thorax. 1997;52:298–299.
  • Angel-Moreno Maroto A, Martínez-Quintana E, Suárez-Castellano L, et al. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford). 2005;44:1326–1327.
  • Cerny J, Licho R, Simkin P, et al. Hypertrophic pulmonary osteoarthropathy disappearance despite lung cancer relapse. South Med J. 2008;101:970–971.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.